Abstract P2-11-08: Risk factors for fibrosis after whole breast radiation therapy in lateral position : A large scale single center experience

Nov 21st, 2018 - Background and Purpose: We previously confirmed the efficacy and safety of our technique of whole breast radiation therapy (WBRT) in isocentric lateral decubitus (ILD) position. The purpose of this work is to evaluate the risk factors for long-term fibrosis in patients treated in ILD position. Material and methods: We studies 832 consecutive female patients with early stage BC treated by conser...

Abstract P2-05-13: Detection of splice variants related to endocrine resistant hormone receptor-positive breast cancer

Feb 19th, 2019 - Introduction: Estrogen receptor is expressed in 75% of breast cancers and is related to a relatively indolent phenotype. Yet, up to 25% of these tumors develop resistance to endocrine therapy. Alternative splicing events are observed in almost every hallmarks of cancer, implying that dysregulation of splicing and cancer progression are closely related. The purpose of this study was to detect sp...

Abstract P2-11-07: Evaluation of lung and heart dose in patients treated with radiation for breast cancer

Nov 22nd, 2018 - BACKGROUND: A recent systematic review of women receiving radiation therapy (RT) for breast cancer combined with modeled estimated risks of mortality from heart disease and lung cancer found that the mean heart dose (MHD) was 4.4 Gy (5.2 Gy for left-sided, 3.7Gy for right-sided) and the mean total lung dose (TLD) was 5.7 Gy. Estimated excess cardiac mortality ranged from 0.3-1.2% and lung cance...

Abstract P2-05-01: Whole genome sequencing reveals enrichment of mutations in mucin gene family in breast cancer diagnosed during pregnancy

Feb 20th, 2019 - Background Pregnancy is known to modulate breast cancer (BC) risk. Different reproductive behaviors have been shown to impact not only the risk of developing BC but also the phenotypes of these tumors. Breast cancer diagnosed during pregnancy (BCP) is a rare disease but could serve as a good model to understand how pregnancy modulates BC biology. In this project, we aim to interrogate the effec...

Abstract P1-01-04: Mutational profiling of breast cancer brain metastases – matched pair analysis of next generation sequencing between primary breast cancer and later developed brain metastases

Apr 3rd, 2019 - Background: Despite increased survival in patients with advanced breast cancer, breast cancer brain metastases (BCBM), remains a final frontier with a mean survival of 3-12 months. The biology facilitating BCBM is not fully understood. Aims: To compare gene expression profiles in primary BC, and later diagnosed, surgically removed BCBM. Material and Methods: A total of 58 BCBM and 46 breast tum...

Abstract P2-11-18: The use of consomic animal models to identify genetic factors that modulate radiation-induced cardiac toxicity

Nov 28th, 2018 - Purpose/Objectives: Radiation therapy is used by more than 50% of breast cancer patients, but radiation doses can be limited by normal tissue side effects. For example, breast cancer radiation therapy can improve breast cancer-specific survival, but increase cardiac deaths in those with left-sided cancers. Identifying genetic factors that can enhance tumor radiation sensitivity while decreasing...

Abstract P1-01-05: Wnt5a induces ROR1 to associate with cortactin, which undergoes tyrosine phosphorylation, and enhances migration of breast cancer cells

Apr 4th, 2019 - Background: ROR1is an evolutionarily conserved, oncoembryonic surface-antigen expressed in breast cancer. Previously, we found that ROR1 can serve as a receptor for Wnt5a, which can induce non-canonical Wnt signaling that enhances cancer-cell migration. Recently we found that Wnt5a could induce ROR1 to complex with a cytoskeletal protein designated HS1, which recruited ARHGEF1, enhanced activat...

Abstract P2-11-01: Effects of radiotherapy on breast cancer outcomes among stage I, low-Recurrence risk, hormone-Sensitive breast cancer: Pooled analysis of individual data from phase III trials

Nov 29th, 2018 - Purpose: Radiotherapy after breast conservation has become the standard of care. Prior meta-analyses of radiotherapy benefits pre-dated availability of gene expression profiling (GEP) to assess recurrence risk and/or did not include all relevant outcomes. This analysis utilized GEP information with individual-level data from seven clinical trials to evaluate the impact of omitting radiotherapy ...

Abstract P1-01-09: BMP4 suppresses the progression of breast cancer through altered expression of metastasis regulating genes

Apr 5th, 2019 - Metastasis is a lethal manifestation of cancer, the development of which is the major cause of death in cancer patients. During a search for metastasis-regulating elements, an inverse correlation was identified between the in vivo tumor expression of bone morphogenetic protein-4 (BMP4) and spontaneous metastasis in a panel of isogenic mammary tumors of varying metastatic capacity. BMP4 is an es...

Abstract P2-11-13: Meta-analysis of local recurrence of invasive breast cancer after electron intraoperative radiotherapy

Nov 30th, 2018 - Background: Electron intraoperative radiotherapy (IORT) can be used during breast conservation surgery to treat early-stage invasive breast cancer. While IORT may be an attractive alternative to traditional post-operative radiotherapy for many patients, its effectiveness in preventing local recurrence is still being evaluated. Using data from current clinical and observational studies, we aimed...

Abstract P1-01-12: Expression of autophagy related genes impacts clinical outcomes of human breast carcinoma and is associated with estrogen and progestin receptor status

Apr 6th, 2019 - The dual role of autophagy in breast cancer initiation, progression and responsiveness to various therapies is the focus of extensive studies. Our goal is to assess the relationship of expression of certain autophagy related genes in primary breast carcinomas to predict risk of recurrence. Our hypothesis includes the caveat that unique gene expression subsets will be deciphered by utilizing Las...

Abstract P2-11-11: Role of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients: A study from the Japanese breast cancer registry

Dec 1st, 2018 - Background: Postmastectomy radiotherapy (PMRT) has been shown to be beneficial in node-positive breast cancer patients. However, the role of PMRT for patients receiving modern neoadjuvant chemotherapy (NAC) are controversial. We aimed to evaluate the efficacy of radiotherapy for breast cancer patients treated with NAC and mastectomy in the Japanese Breast Cancer Registry. Methods: Patients who ...

Abstract P1-01-17: Characterization of novel ESR1 (c.749T>C; p.Met250Thr) mutation in enhancing cellular invasiveness of breast cancer

Apr 7th, 2019 - Emerging evidence has revealed that the mutations in estrogen receptor alpha (ERα) gene (ESR1) is frequently observed in ER+ metastatic breast cancer, and is associated with the aggressively invasive and metastatic phenotype in advanced breast cancer due to the resistance of endocrine therapy. In our previous study, we have identified three novel mutations of ESR1, including ESR1 G74R, D230H an...

Abstract P1-01-03: Preclinical evidence that distant metastases occur via the lymphatic route

Apr 8th, 2019 - Cancer that metastasizes beyond the lymph nodes is almost invariably terminal. Therefore, understanding how cancer metastasizes is a critical aspect to understanding and eventually preventing cancer spreading from tissue to tissue. A major question that remains controversial is whether cancer cells that metastasize to the LNs are able to physically leave the LNs to colonize distant tissues. Mor...

Abstract P2-11-17: Is post mastectomy radiotherapy contributive in pN0-1mi breast cancers patients? Results of a French multi-centric cohort

Dec 3rd, 2018 - Aim: To assess the value of Post-mastectomy radiation therapy (PMRT) in breast cancer patients with no or minimal lymph nodes involvement. Materials and methods: We retrospectively analyzed a French multi-centric cohort of 4283 patients treated between 1980 and 2013, by mastectomy and axillary dissection with or without PMRT. Practices were analyzed according 3 treatment periods (1980-1999, 200...

Abstract P3-07-07: The pan-HER inhibitor, neratinib and wingless-type MMTVs (Wnt)/Wnt regulators in human breast cancer; a biological and clinical perspective

Mar 2nd, 2019 - Background. Neratinib is an orally available tyrosine kinase inhibitor that irreversibly binds and inhibits EGFR, HER2 and HER4 receptor tyrosine kinases. Neratinib has been shown to have clinical activity in HER2-amplified or overexpressed breast cancers and those with HER2 mutations. However, there are indications that it may also work on other subtypes that are not strongly positive for the ...

Abstract P3-07-06: TRIM44 is a possible poor prognostic factor for breast cancer patients and positively regulates NF-κB signaling pathway

Mar 3rd, 2019 - [Background] Many of the tripartite motif (TRIM) proteins, like Efp/TRIM25 which was identified by our group previously (Nature 417, 871-875, 2002), function as E3 ubiquitin ligases, and are thought to be involved in various physiological and pathological processes such as immunity and oncogenesis. In regard to tripartite motif containing 44 (TRIM44), which is an atypical TRIM family protein la...

New Modalities for Genomic Profiling of HER2+ Breast Cancer

Dec 8th, 2017 - New Modalities for Genomic Profiling of HER2+ Breast Cancer From SABCS 2017 Interview with Lee S. Schwartzberg MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA

ER positive breast cancer: Screening for clinical variables to predict late distance disease recurrence

Dec 9th, 2017 - Dr Ivana Sestak speaks with ecancer at SABCS 2017 about screening for clinical variables to predict late distance disease recurrence among women with ER positive breast cancer following endocrine therapy.

CDK 4/6 inhibitors for older women with HR-positive breast cancer

Dec 9th, 2017 - Harpreet Singh speaks at a SABCS 2017 press session about how older women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer who were treated with cyclin-dependent kinase inhibitors 4 and 6 (CDK4/6).